Literature DB >> 11309292

Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes.

S M Kornblau1, I Stiouf, V Snell, D Przepiorka, L C Stephens, R Champlin, F C Marini.   

Abstract

Suicidal lymphocytes could greatly expand the role of allogeneic transplantation by reducing graft-versus-host disease (GVHD) as a barrier to transplantation, but optimization of their use is hindered by the lack of adequate animal models. To develop an animal model that used retrovirally transduced suicidal lymphocytes in a GVHD setting, a well-characterized MHC-matched murine transplant model (B10.BR-->AKR/J) was adapted. B10.BR splenic lymphocytes stimulated with concanavalin A and interleukin 2 were infected with a retrovirus containing the low-affinity nerve growth factor receptor (LNGFR) and the HSV-TK gene and immunomagnetically selected; these LNGFR+/TK+ allogeneic lymphocytes were then cotransplanted with 1 x 10(7) bone marrow cells into lethally irradiated AKR/J recipients. The LNGFR+/TK+ donor lymphocytes persisted in the peripheral circulation for 6 months in both syngeneic and allogeneic settings. Doses of 2 x 10(6) TK+ allogeneic lymphocytes produced GVHD with a severity and time course similar to that induced by naive lymphocytes. Survival of TK+ allogeneic lymphocyte-bearing mice was significantly improved (P = 0.01) when ganciclovir (GCV; 2 mg/day) was administered on days 7-13 post transplant by i.p. injection, demonstrating that GVHD could be prevented. Fluorescence-activated cell sorting analysis demonstrated 4-fold reduction but persistent circulation of LNGFR+ lymphocytes in mice treated with GCV at various time points 1-3 months after transplantation, demonstrating selective killing of GVHD-reactive cells. We conclude that retrovirally transduced LNGFR+/TK+ murine lymphocytes can be produced, persist after transplant, remain alloreactive, and can be killed by GCV administration, resulting in reduced GVHD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309292

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation.

Authors:  Sylvia Borchers; Elena Provasi; Anna Silvani; Marina Radrizzani; Claudia Benati; Elke Dammann; Annika Krons; Julia Kontsendorn; Joerg Schmidtke; Wolfgang Kuehnau; Nils von Neuhoff; Michael Stadler; Fabio Ciceri; Chiara Bonini; Arnold Ganser; Bernd Hertenstein; Eva M Weissinger
Journal:  Hum Gene Ther       Date:  2011-03-30       Impact factor: 5.695

2.  Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography.

Authors:  Amer M Najjar; Pallavi R Manuri; Simon Olivares; Leo Flores; Tiejuan Mi; Helen Huls; Elizabeth J Shpall; Richard E Champlin; Nashaat Turkman; Vincenzo Paolillo; Jason Roszik; Brian Rabinovich; Dean A Lee; Mian Alauddin; Juri Gelovani; Laurence J N Cooper
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

3.  Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

Authors:  Carolina Berger; Mary E Flowers; Edus H Warren; Stanley R Riddell
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

4.  Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes.

Authors:  Steven M Kornblau; Preston G Aycox; Clifton Stephens; L David McCue; Richard E Champlin; Frank C Marini
Journal:  Exp Hematol       Date:  2007-05       Impact factor: 3.084

5.  Imaging long-term fate of intramyocardially implanted mesenchymal stem cells in a porcine myocardial infarction model.

Authors:  Emerson C Perin; Mei Tian; Frank C Marini; Guilherme V Silva; Yi Zheng; Fred Baimbridge; Xin Quan; Marlos R Fernandes; Amir Gahremanpour; Daniel Young; Vincenzo Paolillo; Uday Mukhopadhyay; Agatha T Borne; Rajesh Uthamanthil; David Brammer; James Jackson; William K Decker; Amer M Najjar; Michael W Thomas; Andrei Volgin; Brian Rabinovich; Suren Soghomonyan; Hwan-Jeong Jeong; Jesse M Rios; David Steiner; Simon Robinson; Osama Mawlawi; Tinsu Pan; Jason Stafford; Vikas Kundra; Chun Li; Mian M Alauddin; James T Willerson; Elizabeth Shpall; Juri G Gelovani
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.